Erratum to: Fisetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via TLR4-Mediated NF-κB Signaling Pathway in Rats (Inflammation, (2016), 39, 1, (148-157), 10.1007/s10753-015-0233-y);Fisetin Alleviates Lipopolysaccharide-Induced Acute Lung Injury via TLR4-Mediated NF-κB Signaling Pathway in Rats

Inflammation

Volumn 39, Issue 1, 2016, Pages 148-157

  Feng, Guang ^a   Jiang, Ze yu ^a   Sun, Bo ^c   Fu, Jie ^a   Li, Tian zuo ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

acute lung injury; acute respiratory distress syndrome; fisetin; lipopolysaccharide; NF B; Toll like receptor 4

Indexed keywords

FISETIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; TOLL LIKE RECEPTOR 4; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; FLAVONOID; INTERLEUKIN 6; TLR4 PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; HISTOLOGY; LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY; LUNG PARENCHYMA; MACROPHAGE; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; IMMUNOLOGY; LUNG; MACROPHAGE ACTIVATION; METABOLISM; NEUTROPHIL; PATHOLOGY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BRONCHOALVEOLAR LAVAGE FLUID; ENZYME ACTIVATION; FLAVONOIDS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; NEUTROPHIL INFILTRATION; NEUTROPHILS; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958040759     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-017-0607-4     Document Type: Erratum

References (27)

1. Villar, J., D. Sulemanji, and R.M. Kacmarek. 2014. The acute respiratory distress syndrome: incidence and mortality, has it changed? Current Opinion in Critical Care 20: 3–9.
2. Ware, L.B., and M.A. Matthay. 2000. The acute respiratory distress syndrome. The New England Journal of Medicine 342: 1334–49.
3. Arai, Y., S. Watanabe, M. Kimira, K. Shimoi, R. Mochizuki, and N. Kinae. 2000. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. The Journal of Nutrition 130: 2243–50.
4. Blackwell, T.S., and J.W. Christman. 1997. The role of nuclear factor-kappa B in cytokine gene regulation. American Journal of Respiratory Cell and Molecular Biology 17: 3–9.
5. Hu, R., H. Xu, H. Jiang, Y. Zhang, and Y. Sun. 2013. The role of TLR4 in the pathogenesis of indirect acute lung injury. Frontiers in Bioscience (Landmark Ed) 18: 1244–55.
6. Imai, Y., K. Kuba, G.G. Neely, R. Yaghubian-Malhami, T. Perkmann, G. van Loo, et al. 2008. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235–49.
7. Martin, T.R., and M.M. Wurfel. 2008. A TRIFfic perspective on acute lung injury. Cell 133: 208–10.
8. Spieth, P.M., and H. Zhang. 2014. Pharmacological therapies for acute respiratory distress syndrome. Current Opinion in Critical Care 20: 113–21.
9. Suh, Y., F. Afaq, N. Khan, J.J. Johnson, F.H. Khusro, and H. Mukhtar. 2010. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 31: 1424–33.
10. Khan, N., D.N. Syed, N. Ahmad, and H. Mukhtar. 2013. Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling 19: 151–62.
11. Gelderblom, M., F. Leypoldt, J. Lewerenz, G. Birkenmayer, D. Orozco, P. Ludewig, et al. 2012. The flavonoid fisetin attenuates postischemic immune cell infiltration, activation and infarct size after transient cerebral middle artery occlusion in mice. Journal of Cerebral Blood Flow and Metabolism 32: 835–43.
12. Kim, S.C., S.H. Kang, S.J. Jeong, S.H. Kim, and H.S. Ko. 2012. Inhibition of c-Jun N-terminal kinase and nuclear factor kappa B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells. Immunopharmacology and Immunotoxicology 34: 645–50.
13. Lyu, S.Y., and W.B. Park. 2005. Production of cytokine and NO by RAW 264.7 macrophages and PBMC in vitro incubation with flavonoids. Archives of Pharmacal Research 28: 573–81.
14. Nagai, K., Y. Takahashi, I. Mikami, T. Fukusima, H. Oike, and M. Kobori. 2009. The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes. British Journal of Pharmacology 158: 907–19.
15. Liu, S.H., C.H. Lin, S.K. Hung, J.H. Chou, C.W. Chi, and S.L. Fu. 2010. Fisetin inhibits lipopolysaccharide-induced macrophage activation and dendritic cell maturation. Journal of Agricultural and Food Chemistry 58: 10831–9.
16. Shen, W., J. Gan, S. Xu, G. Jiang, and H. Wu. 2009. Penehyclidine hydrochloride attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. Pharmacological Research 60: 296–302.
17. Ragelle, H., S. Crauste-Manciet, J. Seguin, D. Brossard, D. Scherman, P. Arnaud, et al. 2012. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. International Journal of Pharmaceutics 427: 452–9.
18. Goh, F.Y., N. Upton, S. Guan, C. Cheng, M.K. Shanmugam, G. Sethi, et al. 2012. Fisetin, a bioactive flavonol, attenuates allergic airway inflammation through negative regulation of NF-kappaB. European Journal of Pharmacology 679: 109–16.
19. Yoo, H., S.K. Ku, M.S. Han, K.M. Kim, and J.S. Bae. 2014. Anti-septic effects of fisetin in vitro and in vivo. Inflammation 37: 1560–74.
20. Wilkins, P.A., and T. Seahorn. 2004. Acute respiratory distress syndrome. The Veterinary Clinics of North America. Equine Practice 20: 253–73.
21. Matthay, M.A., and R.L. Zemans. 2011. The acute respiratory distress syndrome: pathogenesis and treatment. Annual Review of Pathology 6: 147–63.
22. Lucas, R., A.D. Verin, S.M. Black, and J.D. Catravas. 2009. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochemical Pharmacology 77: 1763–72.
23. Reumaux, D., M. de Boer, A.B. Meijer, P. Duthilleul, and D. Roos. 2003. Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO. Journal of Leukocyte Biology 73: 841–9.
24. Antonov, A., C. Snead, B. Gorshkov, G.N. Antonova, A.D. Verin, and J.D. Catravas. 2008. Heat shock protein 90 inhibitors protect and restore pulmonary endothelial barrier function. American Journal of Respiratory Cell and Molecular Biology 39: 551–9.
25. Zarember, K.A., and P.J. Godowski. 2002. Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. Journal of Immunology 168: 554–61.
26. He, Z., X. Chen, S. Wang, and Z. Zou. 2014. Toll-like receptor 4 monoclonal antibody attenuates lipopolysaccharide-induced acute lung injury in mice. Experimental Therapeutics and Medecine 8: 871–876.
27. Hoesel, B., and J.A. Schmid. 2013. The complexity of NF-kappaB signaling in inflammation and cancer. Molecular Cancer 12: 86.